<< Back
One Hundred Thousand Procedure Milestone Achieved by Stereotaxis’ Robotic Technology
August 28, 2017 at 9:01 AM EDT

ST. LOUIS, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS) a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that 100,000 procedures have been performed using its Niobe® magnetic navigation system.

“Surpassing 100,000 patients treated is an impressive milestone. It is a testament to the significant clinical value that our technology provides patients and physicians in the electrophysiology field. It also is a reminder of the robust validation of our technology. Stereotaxis stands head-and-shoulders above all others as the global leader in endovascular robotics,” said David Fischel, Chairman and Acting Chief Executive Officer. “I want to thank and congratulate all the employees, physicians, hospital administrators, corporate partners and investors who made reaching this milestone possible. There is a saying that whoever saves a life is considered to have saved an entire world. We take great pride in each patient we treat and life we improve. We look forward to continuing to advance our technology and support robotic ablation practices such that hundreds of thousands of additional patients suffering from arrhythmias can benefit from the precision and safety that robotics provides.”

Stereotaxis’ robotic technology is being utilized by hundreds of physicians at over one hundred hospitals across 30 countries globally. Its clinical value has been documented in nearly 300 peer reviewed publications.

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:

David L. Fischel
Chairman and Acting Chief Executive Officer

Martin C. Stammer
Chief Financial Officer


Primary Logo

Stereotaxis, Inc.
© Copyright Stereotaxis 2020